CCL11 and asthma: Of the 90 and 147 protein analytes assessed for the asthma cohort and COPD cohort, respectively, only eotaxin-1 was significantly upregulated (> 1.5 absolute–fold change following benralizumab treatment compared with placebo in both patient cohorts; FDR < 0.05; Fig. 1a, b).